Sequoia Sciences Llc Competitors

Calico is an Alphabet-founded research and development company whose mission is to harness advanced technologies and model systems to increase our understanding of the biology that controls human aging. We will use that knowledge to devise interventions that enable people to lead longer and healthier lives. Calico’s highly innovative technology labs, its commitment to curiosity-driven discovery science and, with academic and industry partners, its vibrant drug-development pipeline together create an inspiring and exciting place to catalyze and enable medical breakthroughs. Calico is currently seeking exceptional candidates who share our passion for understanding the science of aging and developing therapeutics to address age-related diseases. Explore with us! https://www.calicolabs.com/careers

ZOE combines scientific research with cutting-edge AI to improve the health of millions. We are a remote-first, well-funded scale-up created by the world’s top scientists and backed by founders, investors, and entrepreneurs who have built multi-billion dollar tech companies. Our personalised nutrition program radically reimagines a fundamental human need – eating well for your body. Currently available in the US and the UK, ZOE is already helping tens of thousands of its members adopt a healthier lifestyle. Our collective work and expertise in biology, engineering, data science, and nutrition science have led to multiple breakthrough papers in leading scientific journals such as Nature Medicine, Science, The Lancet, and more. We value inclusivity, transparency, ownership, open-mindedness and diversity. We are passionate about delivering great results and learning in the open. We want our teams to have the freedom to make long-term, high-impact decisions, and the well-being of our teammates and the people around us is a top priority.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases. A Phase 1 SAD/MAD trial of BGE-102 is underway, with topline data including additional MAD cohorts anticipated in 1H26. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging. BioAge offers a comprehensive compensation package, comprehensive health and wellness benefits (medical, dental, and vision insurance), childcare and fertility benefits, and a 401(k) retirement savings plan with matched employer contributions. We pride ourselves on giving employees many opportunities for career development, including a generous annual budget for continued learning and dedication to training and skill development. At BioAge, everyone matters, and we embrace diversity and differences while we learn from each other. We are an equal opportunity employer. BioAge prohibits discrimination and harassment of any type and affords equal employment opportunities to employees and applicants without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law. BioAge conforms to the spirit as well as the letter of all applicable laws and regulations.